Company intelligence / Profile preview

Colibri

Paris, France

Ownership: Private
Development stage: Other

Overview

Kolibri has developed an acoustic wave-based bioreactor platform designed to increase yield while reducing production costs in gene and cell therapy manufacturing. The technology addresses scalability and cost bottlenecks in AAV viral vector production and other cell-based therapies.

Therapeutic areas: Rare Diseases
Modalities: Gene therapy (specifically AAV viral vectors)Cell therapy
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Colibri.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Colibri.

Explore the full profile